| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |